These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 14697898)

  • 41. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The molecular pharmacology of L-deprenyl.
    Gerlach M; Riederer P; Youdim MB
    Eur J Pharmacol; 1992 Jun; 226(2):97-108. PubMed ID: 1639115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of a new antiparkinsonian drug himantane on monoamine oxidase activity].
    Val'dman EA; Voronina TA; Aksenova LN; Buneeva OA; Medvedev AE
    Eksp Klin Farmakol; 2003; 66(5):3-5. PubMed ID: 14650204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of MAO in MPTP toxicity--a review.
    Glover V; Gibb C; Sandler M
    J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.
    Wu RM; Chen RC; Chiueh CC
    Ann N Y Acad Sci; 2000; 899():255-61. PubMed ID: 10863544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells.
    Sanz E; Quintana A; Battaglia V; Toninello A; Hidalgo J; Ambrosio S; Valoti M; Marco JL; Tipton KF; Unzeta M
    J Neurochem; 2008 Jun; 105(6):2404-17. PubMed ID: 18331475
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
    Mandel S; Weinreb O; Amit T; Youdim MB
    Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of selegiline against selective neurotoxins].
    Magyar K
    Vopr Med Khim; 1997; 43(6):504-14. PubMed ID: 9503567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    Tabakman R; Lecht S; Lazarovici P
    Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse.
    Thiffault C; Lamarre-Théroux L; Quirion R; Poirier J
    Brain Res Mol Brain Res; 1997 Mar; 44(2):238-44. PubMed ID: 9073165
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological aspects of (-)-deprenyl.
    Magyar K; Pálfi M; Tábi T; Kalász H; Szende B; Szöko E
    Curr Med Chem; 2004 Aug; 11(15):2017-31. PubMed ID: 15279565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. R-deprenyl: pharmacological spectrum of its activity.
    Magyar K; Szende B; Jenei V; Tábi T; Pálfi M; Szöko E
    Neurochem Res; 2010 Dec; 35(12):1922-32. PubMed ID: 20725780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.
    Yoshida T; Yamada Y; Yamamoto T; Kuroiwa Y
    Xenobiotica; 1986 Feb; 16(2):129-36. PubMed ID: 3083608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW; Hemrick-Luecke SK; Perry KW
    J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
    Tatton WG; Wadia JS; Ju WY; Chalmers-Redman RM; Tatton NA
    J Neural Transm Suppl; 1996; 48():45-59. PubMed ID: 8988461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
    Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.
    Riederer P; Konradi C; Schay V; Kienzl E; Birkmayer G; Danielczyk W; Sofic E; Youdim MB
    Adv Neurol; 1987; 45():111-8. PubMed ID: 3030067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
    Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
    Naoi M; Maruyama W
    Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.